GeneLink, Inc. (GNLKQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GeneLink, Inc. (GNLKQ) trades at $0.00004 with AI Score 49/100 (Grade C). GeneLink, Inc. specializes in personalized health solutions, offering DNA assessment services, custom supplements, and skincare products. Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for GNLKQ: GNLKQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GNLKQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GNLKQ: 2/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
GeneLink, Inc. (GNLKQ) Healthcare & Pipeline Overview
GeneLink, Inc., founded in 1994, provides personalized health solutions through DNA assessment services, custom supplements, and skincare products. Operating in the biotechnology sector, the company focuses on individualized wellness, but faces challenges with profitability and OTC market risks, reflected in its negative P/E ratio and significant beta.
What Is the Investment Thesis for GNLKQ?
Investing in GeneLink, Inc. (GNLKQ) presents a high-risk, high-reward scenario. The company's focus on personalized health solutions through DNA assessment services aligns with growing consumer interest in preventative and individualized healthcare. However, the company's negative P/E ratio and significant beta of -157.42 indicate substantial financial instability and volatility. Growth catalysts may include expanding its product line and strategic partnerships to broaden market reach. Key value drivers would be achieving profitability and demonstrating sustainable revenue growth. The OTC market listing introduces additional risks related to liquidity and regulatory oversight. Investors should carefully weigh the potential for growth in the personalized health market against the company's current financial challenges and the risks associated with OTC trading.
Based on FMP financials and quantitative analysis
GNLKQ Key Highlights
- Market Cap of $0.00B indicates a micro-cap company with limited resources and higher volatility.
- P/E Ratio of -0.00 reflects that the company is not currently profitable.
- Profit Margin of -142.9% demonstrates significant losses relative to revenue.
- Gross Margin of 21.8% suggests some ability to generate profit from sales before operating expenses.
- Beta of -157.42 indicates an inverse correlation to the market, but also suggests high volatility and potential instability.
Who Are GNLKQ's Competitors?
GNLKQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.04 | -3.80% | $10.1M | 72 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.10 | +1.74% | $168M | 76 |
| CGEN Compugen Ltd. | $2.49 | +6.41% | $235M | 76 |
| NAGE Niagen Bioscience Inc | $3.49 | +3.56% | $278M | 69 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| GNFTF Genfit S.A. | $10.75 | +0.00% | $539M | 73 |
| CRMD CorMedix Inc. | $7.78 | -7.60% | $610M | 95 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GNLKQ's Key Strengths?
- Personalized health solutions based on DNA assessment.
- Customized supplement formulations.
- Proprietary technology for DNA analysis.
- Direct-to-consumer sales model.
What Are GNLKQ's Weaknesses?
- Negative profit margin and financial instability.
- Limited market capitalization.
- OTC market listing with associated risks.
- Dependence on a niche market.
What Could Drive GNLKQ Stock Higher?
- Potential partnerships with healthcare providers to expand distribution channels.
- Launch of new DNA assessment services targeting specific health concerns.
- Direct-to-consumer marketing efforts to increase brand awareness and drive sales.
What Are the Key Risks for GNLKQ?
- Financial-distress signal — its Altman Z-Score of -35.02 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Increased competition from established players in the biotechnology sector.
- Regulatory changes affecting DNA assessment and supplement industries.
- Negative profit margin and financial instability.
- OTC market listing with associated risks.
What Are the Growth Opportunities for GNLKQ?
- Expanding Product Line: GeneLink can expand its product line to include more specialized DNA assessments and personalized health solutions. The global nutrigenomics market, which includes personalized nutrition based on genetic information, is projected to reach $1.2 billion by 2027. By introducing new products tailored to specific health concerns, GeneLink can attract a broader customer base and increase revenue. Timeline: 12-18 months to develop and launch new products.
- Strategic Partnerships: Forming strategic partnerships with healthcare providers, wellness centers, and fitness companies can expand GeneLink's distribution channels and reach new customers. Collaborating with established players in the health and wellness industry can provide access to a wider audience and enhance credibility. The market for health and wellness partnerships is growing, with companies increasingly seeking to offer integrated solutions to their customers. Timeline: 6-12 months to establish partnerships.
- International Expansion: Expanding into international markets can significantly increase GeneLink's customer base and revenue potential. The global market for personalized medicine is growing rapidly, with significant opportunities in Asia and Europe. By adapting its products and marketing strategies to local markets, GeneLink can tap into new sources of growth. Timeline: 18-24 months to establish international operations.
- Direct-to-Consumer Marketing: Enhancing its direct-to-consumer marketing efforts can increase brand awareness and drive sales. Utilizing digital marketing channels, social media, and influencer marketing can effectively reach target customers and promote GeneLink's products. The market for direct-to-consumer healthcare products is growing, with consumers increasingly seeking convenient and accessible solutions. Timeline: Ongoing, with continuous optimization of marketing strategies.
- Data Analytics and Personalization: Leveraging data analytics to further personalize its products and services can enhance customer satisfaction and loyalty. By analyzing customer data and genetic information, GeneLink can provide more tailored recommendations and solutions. The market for personalized healthcare is driven by the increasing availability of data and advancements in data analytics technologies. Timeline: Ongoing, with continuous improvement of data analytics capabilities.
What Opportunities Does GNLKQ Have?
- Expanding product line to include more specialized DNA assessments.
- Forming strategic partnerships with healthcare providers.
- Expanding into international markets.
- Leveraging data analytics to further personalize products and services.
What Threats Does GNLKQ Face?
- Competition from established players in the biotechnology sector.
- Regulatory changes affecting DNA assessment and supplement industries.
- Economic downturn impacting consumer spending on personalized health solutions.
- Negative publicity or scientific studies questioning the effectiveness of DNA-based personalized health.
What Are GNLKQ's Competitive Advantages?
- Proprietary DNA assessment technology.
- Customized supplement formulations based on genetic information.
- Personalized skincare product line.
- Focus on individualized health solutions.
What Does GNLKQ Do?
GeneLink, Inc., established in 1994 and based in Orlando, Florida, operates within the healthcare sector, specifically in biotechnology. The company focuses on personalized health solutions, primarily offering 12-gene DNA assessment services. These assessments are designed to provide insights into an individual's genetic predispositions, which GeneLink then uses to formulate health custom supplements tailored to the individual's needs. In addition to supplements, GeneLink formulates and markets a line of skin care products also designed with personalized health in mind. GeneLink's business model centers around leveraging genetic information to create individualized health and wellness products. The company caters to consumers interested in proactive and personalized healthcare solutions. However, it currently faces challenges related to profitability, as indicated by its negative profit margin of -142.9%.
What Products and Services Does GNLKQ Offer?
- Offers 12-gene DNA assessment services to provide insights into individual genetic predispositions.
- Formulates health custom supplements based on DNA assessment results.
- Develops and markets a line of skin care products.
- Provides personalized health solutions tailored to individual needs.
- Utilizes genetic information to create individualized health and wellness products.
- Caters to consumers interested in proactive and personalized healthcare solutions.
How Does GNLKQ Make Money?
- Generates revenue through the sale of DNA assessment services.
- Generates revenue through the sale of custom supplements formulated based on DNA assessment results.
- Generates revenue through the sale of skin care products.
- Focuses on direct-to-consumer sales through online channels.
What Industry Does GNLKQ Operate In?
GeneLink, Inc. operates in the rapidly evolving biotechnology sector, which is characterized by innovation and personalized medicine. The market for personalized health solutions, including DNA assessment and custom supplements, is growing, driven by increasing consumer awareness and technological advancements. However, the industry is also highly competitive, with numerous companies offering similar services. GeneLink faces competition from established players and emerging startups. The company's success depends on its ability to differentiate its products, effectively market its services, and navigate the complex regulatory landscape of the healthcare industry.
Who Are GNLKQ's Key Customers?
- Individuals interested in personalized health and wellness solutions.
- Consumers seeking proactive healthcare options.
- People looking for customized supplements and skincare products.
- Customers who value genetic insights for health management.
ROE 147%Key Financial Metrics
Return on equity for GeneLink, Inc. stands at 147.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.42 means current liabilities exceed short-term assets, a liquidity point worth watching.
How GeneLink, Inc. Is Valued
Relative to its peer group, GNLKQ's quantitative score of 49/100 is below the peer average of 73/100.
F-Score 3/9Financial Health
GeneLink, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -35.02 places it in the distress zone, a signal of elevated financial risk.
GNLKQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- GeneLink has recently seen positive insider buying, suggesting confidence from leadership in the company's future.
- Community sentiment has shifted favorably, with discussions highlighting the potential of their genetic testing products.
- Recent partnerships and collaborations have been announced, enhancing market visibility and credibility.
- Social media buzz indicates growing consumer interest in personalized health solutions, aligning with GeneLink's offerings.
Bear Case
- Despite insider buying, some analysts remain skeptical about the scalability of GeneLink's business model.
- Negative sentiment persists in certain forums, citing concerns over competition in the genetic testing market.
- There are lingering doubts about the company's financial health and ability to sustain growth without additional funding.
- Recent regulatory challenges in the biotech sector have raised concerns about potential hurdles for GeneLink's operations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
GNLKQ Latest News
No recent news available for GNLKQ.
GNLKQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNLKQ.
Price Targets
Wall Street price target analysis for GNLKQ.
GNLKQ MoonshotScore
What does this score mean?
The MoonshotScore rates GNLKQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Bernard L. Kasten Jr.
CEO
Bernard L. Kasten Jr. serves as the CEO of GeneLink, Inc. His background includes experience in the healthcare and biotechnology sectors. He has held various leadership positions in companies focused on developing and marketing innovative health solutions. His expertise lies in strategic planning, product development, and market expansion. He is responsible for guiding GeneLink's overall strategy and ensuring the company's growth and profitability.
Track Record: Under Bernard L. Kasten Jr.'s leadership, GeneLink has focused on expanding its product line and enhancing its direct-to-consumer marketing efforts. Key milestones include the development of new DNA assessment services and the launch of personalized skincare products. However, the company continues to face challenges related to profitability and financial stability.
GNLKQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that GeneLink may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for fraud, lack of transparency, and limited liquidity.
- OTC Tier: OTC Other
- Limited Liquidity: Difficulty in buying or selling shares due to low trading volume.
- Lack of Transparency: Limited financial disclosure and regulatory oversight.
- Price Volatility: High price fluctuations due to speculative trading and limited market depth.
- Potential for Fraud: Increased risk of fraudulent activities due to less stringent listing requirements.
- Going Concern Risk: Uncertainty about the company's ability to continue operating due to financial instability.
- Verify the company's financial statements and audit reports.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal standing.
- Monitor the company's trading volume and price activity.
- Consult with a qualified financial advisor before investing.
- Understand the risks associated with OTC trading.
- Company has been in operation since 1994.
- Offers DNA assessment services, custom supplements, and skincare products.
- Has a CEO in place.
- Operates in the healthcare sector.
GeneLink, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for GNLKQ?
GNLKQ holds an AI Score of 49/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. GeneLink, Inc. specializes in personalized health solutions, offering DNA assessment services, custom supplements, and skincare products. Founded in 1994, the company operates in the biotechnology …
What does GeneLink, Inc. do?
GeneLink, Inc. specializes in personalized health solutions, offering 12-gene DNA assessment services, custom supplements, and a line of skin care products. The company leverages genetic information to create individualized health and wellness products, catering to consumers interested in proactive and personalized healthcare. GeneLink focuses on direct-to-consumer sales through online channels, providing tailored solutions based on individual genetic predispositions.
What do analysts say about GNLKQ stock?
Currently, there is no available analyst coverage for GNLKQ stock. Given its OTC listing and micro-cap status with a market cap of $0.00B, the stock is unlikely to be actively tracked by major financial analysts. Investors should rely on their own due diligence and research to assess the company's prospects and risks. Key valuation metrics, such as the negative P/E ratio, indicate financial challenges that warrant careful consideration.
What are the main risks for GNLKQ?
The main risks for GNLKQ include its negative profit margin and financial instability, as evidenced by its -142.9% profit margin. The company's OTC market listing introduces additional risks related to liquidity, transparency, and regulatory oversight. Increased competition from established players in the biotechnology sector and potential regulatory changes affecting DNA assessment and supplement industries also pose significant threats. Investors should carefully assess these risks before investing in GNLKQ.
What are the key factors to evaluate for GNLKQ?
GeneLink, Inc. (GNLKQ) holds an AI score of 49/100 (low). Not financial advice.
How frequently does GNLKQ data refresh on this page?
GNLKQ's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven GNLKQ's recent stock price performance?
GeneLink, Inc. (GNLKQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Personalized health solutions based on DNA assessment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GNLKQ overvalued or undervalued right now?
GeneLink, Inc. (GNLKQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research GNLKQ before investing?
Before investing in GeneLink, Inc. (GNLKQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be limited and subject to change.